R

Rigel Pharmaceuticals

D
RIGL
USD
0.02
(0.1468%)
Market Closed
663.00
Volume
-1.29
EPS
-
Div Yield
-17.714286
P/E
239,995,486.28
Market Cap
Today
0.1468%
1 Week
5.206%
1 Month
7.351%
6 Months
-0.438%
12 Months
24.566%
Year To Date
-6.575%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SGEN
(%)
USD
I
INCY
1.67
(2.5625%)
USD
A
ALNY
3.06
(1.1203%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
A
ARWR
0.35
(1.6851%)
USD
REGN
REGN
11.33
(0.9948%)
USD
B
BIIB
3.82
(1.9334%)
USD
GILD
GILD
0.015
(0.0179%)
USD

Title:
Rigel Pharmaceuticals Inc

Sector:
Healthcare
Industry:
Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Do you need help or have a question?
Contact Us